Does Aetna (CVS Health) Cover Wegovy?

Aetna's Coverage Policy for Wegovy

Aetna (CVS Health) includes Wegovy on its commercial formularies as a covered medication for chronic weight management, but places it behind two gates: prior authorization (PA) and step therapy. The policy applies to both PPO and HMO products, though specific plan documents can modify these requirements.

Aetna's clinical policy bulletins classify semaglutide 2.4 mg as medically necessary when prescribed for adults with obesity (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 kg/m²) with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia. This mirrors the FDA-approved indication for Wegovy, which received approval in June 2021 for chronic weight management in adults with obesity or overweight plus at least one comorbidity [1]. Pediatric coverage (ages 12 and older) varies by plan and often requires additional documentation from a pediatric endocrinologist.

The clinical rationale behind covering Wegovy rests on trial data. In STEP-1 (N=1,961), participants receiving semaglutide 2.4 mg weekly lost a mean of 14.9% of body weight at 68 weeks compared with 2.4% in the placebo group [2]. That magnitude of weight reduction exceeds what older anti-obesity medications typically produce. Aetna's formulary committee acknowledged this efficacy but balanced it against the drug's cost, placing Wegovy in a non-preferred specialty tier with mandatory utilization controls.

Self-funded employer plans administered by Aetna may have different coverage terms. Some employers exclude anti-obesity medications entirely, while others apply more lenient PA criteria. Check your specific plan's Summary of Benefits and Coverage (SBC) or call the number on the back of your Aetna member ID card.

Prior Authorization Requirements

Getting PA approval from Aetna for Wegovy takes documentation and patience. The process is rated moderate-high in difficulty, and your prescriber should expect to submit clinical records rather than just a prescription.

Aetna's PA form for Wegovy generally requires the following: a documented BMI calculated from a measured height and weight (not self-reported), a diagnosis of obesity or overweight with comorbidity, evidence of participation in a structured diet and exercise program for at least 6 months, and documentation that at least one formulary-preferred weight-management medication was tried and either failed or was contraindicated [3]. The Endocrine Society's 2015 clinical practice guideline on pharmacological management of obesity recommends pharmacotherapy as an adjunct to lifestyle modification when BMI thresholds are met, and Aetna's criteria align with this framework.

Your prescriber submits the PA request to CVS Caremark (Aetna's pharmacy benefit manager). Standard review takes 5 to 15 business days. Urgent requests, when clinically justified, can receive a 24-to-72-hour expedited review. Common reasons for denial include incomplete documentation, failure to demonstrate a prior medication trial, or a BMI that does not meet threshold after recalculation.

A practical tip: have your prescriber attach office visit notes showing serial weight measurements over 6 months, along with a letter specifying which medications were tried, at what doses, for how long, and why they were insufficient. Vague statements like "patient tried diet and exercise" are the most common reason PA requests get bounced back.

Formulary Tier and Cost Breakdown

Wegovy sits on Tier 4 or Tier 5 (non-preferred specialty) on most Aetna CVS Caremark formularies, which means higher out-of-pocket costs compared with generic or preferred-brand medications.

Without insurance, the list price for Wegovy is $1,349 per month. With Aetna coverage after PA approval, your actual cost depends on your plan's specialty tier copay or coinsurance structure. Typical ranges for Aetna commercial plans:

• Fixed copay plans: $150 to $300 per 28-day fill
• Coinsurance plans: 25% to 50% of the drug cost after deductible, which translates to roughly $337 to $675 per month at list price
• High-deductible health plans (HDHPs): full list price until the deductible is met, then coinsurance applies

These figures shift substantially depending on whether your employer negotiated rebates or whether you have reached your plan's out-of-pocket maximum. Wegovy costs count toward both the deductible and out-of-pocket maximum on most Aetna plans, so members with high utilization earlier in the year may see lower costs later.

For comparison, a 2022 analysis published in JAMA Network Open found that out-of-pocket costs for GLP-1 receptor agonists were a primary driver of medication discontinuation, with patients paying more than $200 per month being 2.3 times more likely to stop treatment within 12 months [4]. This underscores why understanding your tier placement and available savings programs matters before starting therapy.

Step Therapy: What You Must Try First

Aetna requires step therapy for Wegovy on most commercial plans. This means your prescriber must document that you tried and failed (or cannot take) at least one lower-cost anti-obesity medication before Wegovy will be approved.

The medications Aetna typically accepts as step therapy include:

• Phentermine (generic, ~$30 to $75/month): a sympathomimetic amine approved for short-term use. Must be tried for at least 3 months.
• Phentermine-topiramate ER (Qsymia): a combination pill. Trial period is usually 3 to 6 months at the recommended dose.
• Naltrexone-bupropion ER (Contrave): an opioid antagonist/antidepressant combination. Trial period typically 3 months at maintenance dose.

"Failure" in Aetna's framework means less than 5% total body weight loss during the trial period, intolerable side effects documented in the medical record, or a medical contraindication (such as uncontrolled hypertension for phentermine, or seizure history for naltrexone-bupropion).

Some prescribers view step therapy as a barrier rather than a clinical pathway. But data from the American Association of Clinical Endocrinology (AACE) 2023 obesity algorithm suggest that trialing a lower-cost agent first is reasonable when the clinical situation permits, because a subset of patients (roughly 15% to 20% in real-world data) do achieve clinically meaningful weight loss on these older medications [5]. For patients who do not respond, the documented failure strengthens the PA case for Wegovy considerably.

Step therapy exceptions exist. If your prescriber can document a contraindication to all step-therapy agents (for example, a patient with epilepsy, substance use disorder, and cardiovascular disease that contraindicates phentermine, naltrexone-bupropion, and phentermine-topiramate respectively), Aetna may waive the step requirement. This exception request is submitted alongside the PA.

How to Appeal an Aetna Denial for Wegovy

A denied PA is not the end. Aetna's appeal process has two levels, and denial overturn rates for anti-obesity medications have been increasing as clinical evidence for GLP-1 agonists grows.

First-level internal appeal. You or your prescriber must file this within 180 days of the denial. Submit a written appeal letter that addresses each specific reason listed in the denial notice. If the denial cited "insufficient documentation of lifestyle modification," attach dietitian visit records, gym membership logs, or a structured program summary. If it cited "step therapy not completed," provide records of the prior medication trial including start date, duration, dose, and outcome. Aetna must respond within 30 days for standard appeals or 72 hours for expedited appeals.

External review. If the internal appeal is denied, you have the right to an independent external review under the Affordable Care Act's external review provisions. An independent review organization (IRO) examines the case using the same clinical criteria. External reviews are binding on Aetna. According to data from state insurance departments, external review overturn rates for specialty medication denials range from 40% to 60%, though specific rates for anti-obesity medications are not separately reported [6].

Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, has stated: "The appeals process for anti-obesity medications requires persistence. Clinicians who provide detailed, evidence-based documentation of medical necessity, citing specific trial data and guideline recommendations, see significantly higher approval rates on appeal."

A strong appeal letter should reference the patient's specific BMI history, comorbidities that respond to weight loss (citing the STEP series trials showing improvements in cardiometabolic markers), and the failure of prior interventions with specific dates, doses, and measured outcomes.

Using the Novo Nordisk Savings Card with Aetna

Commercially insured Aetna members may be eligible for the Novo Nordisk Wegovy savings card, which can reduce out-of-pocket costs to as low as $0 per fill for up to 13 fills over 12 months, with a maximum benefit per fill.

Eligibility requirements for the savings card:

• Must have commercial insurance (not Medicare, Medicaid, or other government-funded programs)
• Must have a valid prescription for Wegovy
• The savings card covers the difference between your plan's copay/coinsurance and the savings-card benefit cap

There are limitations. The savings card has a per-fill maximum benefit (typically $200 to $500 depending on the current program terms), so if your Aetna plan's coinsurance leaves you owing $675 per month, the savings card might bring that down to $175 to $475 rather than $0. Terms change periodically, so verify current limits on the manufacturer's website or by calling the number on the savings card.

One timing consideration: the savings card benefit resets annually, and if you start mid-year, you get fewer covered fills before the reset. Some patients coordinate their Wegovy start date with their plan's benefit year to maximize savings-card value.

Members on Aetna Medicare Advantage plans are not eligible for the savings card. Medicare Part D coverage for Wegovy expanded under the Inflation Reduction Act provisions, but coverage terms differ substantially from commercial plans.

Reauthorization and Ongoing Coverage

Aetna's initial PA approval for Wegovy typically lasts 6 to 12 months. Before the authorization expires, your prescriber must submit a reauthorization request documenting clinical response.

Reauthorization criteria generally require evidence of at least 5% total body weight loss from baseline during the initial authorization period. If you started at 240 lbs, Aetna expects documentation showing you have lost at least 12 lbs. This threshold aligns with the FDA's labeling recommendation to reassess treatment in patients who have not achieved at least 5% weight loss after 16 weeks on the maintenance dose [1].

Patients who meet the 5% threshold generally receive reauthorization without difficulty. Those who fall short may face denial, though extenuating circumstances (medication interruptions due to supply shortages, intercurrent illness, or dose-titration delays) can be documented to support continued coverage.

A key data point: in STEP-1, 83.5% of participants receiving semaglutide 2.4 mg achieved at least 5% weight loss by week 68, compared with 31.1% on placebo [2]. This means the vast majority of patients who take Wegovy as prescribed should meet Aetna's reauthorization threshold, but the 16.5% who did not respond in the trial may face coverage discontinuation.

Dr. Robert Kushner, professor of medicine at Northwestern University Feinberg School of Medicine, has noted: "Insurers are increasingly applying outcome-based reauthorization criteria for anti-obesity medications. Documenting weight, waist circumference, and improvement in comorbidities like hemoglobin A1c or blood pressure at each visit creates the clinical record needed for smooth reauthorization."

Aetna Medicare Advantage and Medicaid Plans

Coverage for Wegovy on Aetna Medicare Advantage and Medicaid managed-care plans differs substantially from commercial coverage.

Medicare Advantage. Historically, Medicare Part D excluded anti-obesity medications. The Treat and Reduce Obesity Act and subsequent CMS guidance began expanding coverage, and the Inflation Reduction Act of 2022 included provisions allowing Part D coverage of FDA-approved anti-obesity medications when prescribed for a covered indication. However, individual Aetna Medicare Advantage Part D plans may still impose restrictions beyond those on commercial plans, including narrower BMI criteria, mandatory specialist referrals, and lower annual fill limits. Check your plan's formulary or call Aetna's Medicare member services line.

Medicaid. Aetna manages Medicaid plans in several states. Coverage for Wegovy under Medicaid varies by state. Some state Medicaid programs cover anti-obesity medications with PA; others exclude the category. A 2023 analysis in Obesity journal found that only 17 state Medicaid programs covered at least one GLP-1-based anti-obesity medication as of late 2022, though that number has grown since [7].

Timeline: From Prescription to First Injection

Knowing what to expect helps reduce frustration. Here is a realistic timeline for an Aetna member starting Wegovy:

Week 1. Prescriber visit. BMI documented, comorbidities assessed. If step therapy has not been completed, the prescriber either documents a prior trial or starts one.

Weeks 2 to 14. Step-therapy trial (if required). Minimum 3-month trial of a formulary-preferred medication at adequate dose.

Week 15. Prescriber submits PA to CVS Caremark. Includes documentation of BMI, comorbidities, lifestyle intervention, and step-therapy failure.

Weeks 15 to 18. PA review period. Standard decisions take 5 to 15 business days.

Week 18 (if approved). Prescription sent to specialty or retail pharmacy. Wegovy ships or is available for pickup within 3 to 7 days, supply permitting.

Week 19. First injection at the 0.25 mg starting dose. Dose titration follows the FDA label: 0.25 mg for 4 weeks, 0.5 mg for 4 weeks, 1 mg for 4 weeks, 1.7 mg for 4 weeks, then 2.4 mg maintenance.

For patients who have already completed step therapy with another prescriber, bring those records to your appointment. This can eliminate the 3-month step-therapy window entirely.